

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00	A1	(11) International Publication Number: WO 95/12406 (43) International Publication Date: 11 May 1995 (11.05.95)
(21) International Application Number: PCT/US94/12751 (22) International Filing Date: 4 November 1994 (04.11.94) (30) Priority Data: 08/148,160 4 November 1993 (04.11.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/148,160 (CIP) Filed on 4 November 1993 (04.11.93) (71) Applicant (for all designated States except US): ADEZA BIOMEDICAL [US/US]; 1240 Elko Drive, Sunnyvale, CA 94089 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TERA0, Toshihiko [JP/JP]; 4872-29 Hamamatsu City, Shizuoka 431-31 (JP). KANAYAMA, Naohiro [JP/JP]; 3600 Handa-cho Hamamatsu City, Shizuoka 431-31 (JP). CASAL, David [US/US]; 574 Cutwater Lane, Foster City, CA 94404 (US). (74) Agents: CAGAN, Felissa, H. et al.; Morrison & Foerster, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>
(54) Title: USE OF URINASTATIN-LIKE COMPOUNDS TO PREVENT PREMATURE DELIVERY		
(57) Abstract The present invention provides a method of diagnosing and treating a pregnant female at risk for impending preterm delivery. The method comprises the step of diagnosing imminent preterm delivery by testing with a method that has a sensitivity of at least 80 % and a specificity of at least 80 %, or by testing for fetal fibronectin in the female's vaginal or cervical secretions. If imminent preterm delivery is indicated by the test, the next step comprises administering to the female a combination of a tocolytic agent, at least one urinastatin-like compound, and at least one antibiotic. Also provided is a pharmaceutical composition of MGMTSRFYNGTSMA, RAFIQLWAFDAVKGK and an antibiotic.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

5 USE OF URINASTATIN-LIKE COMPOUNDS TO PREVENT
 PREMATURE DELIVERY

FIELD OF USE

10 This invention relates to the diagnosis and
 treatment of pregnant females at risk for preterm
 delivery. This invention is a method of diagnosing
 females at risk for preterm delivery and of treating
 such females with a combination of a tocolytic, a
15 urinastatin-like compound, and an antibiotic.

BACKGROUND

 In spite of the advances in health care and
 particularly perinatology, the preterm delivery of
20 babies continues to be a major public health problem
 because of its association with infant morbidity and
 mortality. For example, the results of a multicenter
 trial spanning several years of experience showed that
 infants born prematurely, i.e., between 20 and 36
25 weeks gestation, accounted for 9.6% of births (Copper
 et al. Amer. J. Obstet. Gynecol. 168: 78, 1993). In
 that study, 83% of infant deaths occurred in
 gestations delivering prior to 37 weeks, and 66%
 involved gestations of less than 29 weeks.

30 Serious neonatal complications also decrease
 as the period of gestation increases. The incidence
 of neonatal respiratory distress syndrome decreases
 markedly after 36 weeks of gestation. Likewise, the
 incidence of neonatal patent ductus arteriosus and
35 necrotizing enterocolitis decreases markedly after 32

-2-

weeks of gestation. According to Creasy, "high grade intraventricular hemorrhage diminishes rapidly after 27 weeks and is virtually absent after 32 weeks" (Creasy, Amer. J. Obstet. Gynecol. 168: 1223, 1993).

- 5 Thus, extending the length of pregnancy beyond 32 weeks and preferable beyond 36 weeks could reduce the incidence of neonatal morbidity and virtually eliminate major causes of neonatal mortality.

- 10 According to Creasy, the incidence of preterm delivery in the United States is rising. When preterm delivery is defined as births occurring before 37 weeks of gestation, the incidence has risen from 9.4% in 1981 to 10.7% in 1989, accounting for approximately 425,000 of the 4,000,000 annual births
15 in the United States of America.

- There are several problems related to the rising incidence of preterm delivery in the United States. One problem is that physicians are unable to accurately predict which pregnancies are at risk.
- 20 Factors known to be associated with elevated chronic risk of preterm delivery in otherwise asymptomatic women are low maternal socioeconomic status, lack of prenatal care, illicit drug use during pregnancy, previous preterm delivery, assisted reproductive
25 techniques used in the current pregnancy (such as in vitro fertilization or gamete intra-fallopian transfer), smoking, uterine anomalies, and stress. (Morrison, Amer. J. Obstet. Gynecol. 168:538, 1993; Creasy, Amer. J. Obstet. Gynecol. 168:1223, 1993).
- 30 Unfortunately, the majority of preterm births cannot be related to obvious causes, and even known causes may not necessarily be detectable or correctable. In fact, approximately one half of all preterm births occur in women who are pregnant for the first time and
35 have no known risk factors for preterm delivery.

-3-

Even when women complain of symptoms frequently associated with acute risk of preterm delivery, it is often difficult to distinguish harmless symptoms from those associated with imminent prematurity. Many symptoms such as uterine contractions, change in vaginal discharge, abdominal discomfort, pelvic heaviness or change in cervical dimensions (effacement and dilatation) may harmlessly occur as normal variants in some pregnancies, while similar symptoms in other pregnancies can be associated with impending preterm delivery.

The majority of pregnant women who seek unscheduled emergency obstetrical care have complaints of excessive or painful uterine contractions of the uterus. Another frequent complaint is a tightening or pressure sensation which can indicate Braxton Hicks contractions of the uterus. Thus, physicians are often faced with the diagnostic dilemma of differentiating "true" from "false" labor with clinical information of limited diagnostic value. (Pircon et al., Amer. J. Obstet. Gynecol. 161:775, 1989) Copper et al. attempted to diagnose preterm labor using uterine activity (4 contractions/20 minutes or 8 contractions/60 minutes) coupled "with at least one of the following: ruptured membranes, cervical changes, cervical dilatation ≥ 2.0 cm, or cervical length ≤ 1.0 cm." Copper reported that this assessment was complicated by the fact that "contractions, regardless of the measure of frequency," normally increase during pregnancy.

The presence of advanced cervical dilatation (or effacement) is clinically important for determining risk of delivery (Morrison, Obstet. Gynecol. 76 (Suppl. 1)55, 1990). Many clinical studies have demonstrated that cervical dilatation of

-4-

greater than 3 cm is frequently associated with imminent delivery regardless of gestational age. Unfortunately, not all women with symptoms of threatened preterm delivery who ultimately deliver prematurely have advanced cervical dilatation when they present for emergency obstetrical care (Lockwood, N. Engl. J. Med. 325:669, 1991). Moreover, among the many clinical symptoms and signs associated with preterm labor or delivery, cervical dilatation is not necessarily the first clinical change noted. Typically, women with preterm labor who ultimately deliver prematurely seek obstetrical care for non-specific symptoms such as uterine activity, change in vaginal discharge, or abdominal discomfort which frequently precede cervical dilatation. Given the poor predictive power of these clinical signs and symptoms, "clinicians do not have a good discriminator of false versus true labor", resulting in as many as 50% of patients with "false" labor delivering early (Morrison et al., Amer. J. Obstet. Gynecol. 168:538, 1993).

In contrast, a more potent method of diagnosing patients at risk for preterm delivery is emerging. The presence of fetal fibronectin in cervical or vaginal secretions has been shown to be an accurate predictor for preterm delivery in women with symptoms suggestive of threatened preterm delivery (Lockwood et al., *ibid.*). A control group of women with uncomplicated pregnancies who delivered at term rarely had cervicovaginal concentrations of fetal fibronectin greater than 50 ng/ml at weeks 21-37 of gestation. In contrast, approximately 94% of women with preterm rupture of amniotic membranes had significantly elevated fetal fibronectin concentrations. But more importantly, about 50% of

-5-

women with intact amniotic membranes and preterm uterine contractions had elevated concentrations of fetal fibronectin and more than 80% of these women delivered prematurely. Conversely, greater than 80% of women with intact membranes who did not have detectable cervicovaginal fetal fibronectin delivered at term. Thus, fetal fibronectin was demonstrated to be both a sensitive and specific predictor of preterm delivery.

Not surprisingly, the lack of available specific and sensitive indicators of preterm delivery risk among symptomatic women limits the ability of physicians to appropriately treat women judged to be at risk. In addition, there is considerable controversy in the obstetrical community regarding the therapeutic efficacy of available treatment regimens. Of course, assessment of any treatment regimen is complicated by the fact that perhaps as many as half of women diagnosed with preterm labor may not have the disease.

Effective and judicious treatment of preterm labor, especially in earlier gestation, is critical to the development of the fetus. As discussed above, births after 32-34 weeks of gestation are associated with lower rates of neonatal mortality and severe neonatal morbidity. Thus, prolongation of pregnancy and subsequent reduction of preterm delivery rates might be expected to lower neonatal morbidity and mortality. Unfortunately, in spite of the fact that obstetricians have identified more women as candidates for preterm labor treatment (known as tocolysis) over the last decade, the incidence of preterm delivery has actually increased over the same time span (Creasy, Amer. J. Obstet. Gynecol. 168:1223, 1993). The fact that the preterm delivery rate has not improved over

-6-

the past decade is due not only to the inability of physicians to accurately identify patients truly in need of treatment but also to the failure of commonly available tocolytic drugs to impede the progress of labor.

5 Numerous controlled, clinical trials have been conducted to evaluate the clinical merits of various treatment regimens including bedrest, hydration, antibiotics, beta-adrenergic agonists, 10 prostaglandin inhibitors, and calcium antagonists. The cumulative experience of these trials has clearly shown that common strategies for tocolytic intervention do not reproducibly prevent preterm delivery although they may be modestly effective for 15 prolongation of pregnancy. Unfortunately, modest gains do not necessarily translate into improved neonatal outcome. As Creasy has noted, "numerous trials of prophylactic beta-adrenergic tocolytic usage with relatively low doses of medication have also not 20 shown benefit in either singleton or multiple gestation".

The role of infection in preterm labor and use of antibiotics has been studied extensively, particularly in the context of premature rupture of 25 the membranes (PROM). For example, a controlled clinical trial of antibiotic treatment with the broad spectrum erythromycin and ampicillin was associated with prolongation of gestation compared to the absence of antibiotics (McGregor and French, Obstet. Gynecol. Clin. North Amer. 19:327-38, 1992). In contrast, a 30 controlled study of prophylactic erythromycin therapy showed no decrease in the incidence of maternal or neonatal infectious morbidity; however, in patients "destined to have chorioamnionitis and 35 oligohydramnios", pregnancy was significantly

-7-

prolonged (Mercer et al., Amer. J. Obstet. Gynecol. 166:794, 1992).

5 Only four trials evaluating the effect of antibiotics in treatment of women with preterm labor and intact membranes have been conducted. "Three of the four groups report an apparent prolongation of pregnancy with antibiotic therapy without impact on aggregate birth weight or perinatal mortality of the resultant infants" (Kirschbaum, Amer. J. Obstet. Gynecol. 168:1239, 1993).
10 The results of these trials are difficult to interpret due to the use of different antibiotics, different clinical criteria for diagnosis of preterm labor and small numbers.

15 More promising strategies for reducing the incidence of preterm birth and lowering rates of neonatal morbidity and mortality may involve use of combination therapies, i.e., simultaneously using multiple, independent drugs. Kanayama (Nihon Sanka Fujinka Gakkai Zasshi. 44:110-15, 1992) reported a
20 clinical study of women who showed signs of impending premature delivery. None of the patients had PROM, all were between the 24th and 35th weeks of pregnancy, and all had a "tocolysis index of 3-4", which was described as "imminent premature delivery of an
25 intermediate degree." The tocolysis index is a relative index of delivery risk in which various risk factors for preterm delivery including status of amniotic membranes (rupture versus intact membranes), presence or absence of vaginal bleeding, estimation of
30 cervical dilatation, and frequency of uterine contractions are semi-quantitatively assessed and scored, as indicated below.

-8-

		<u>Tocolysis Index</u>			
		<u>0 pts</u>	<u>1 pt</u>	<u>2 pts</u>	<u>3 pts</u>
	Cervical Dilation	0 cm	1 cm	2 cm	3 cm
5	Vaginal Bleeding	none	---	spotting	
	bleeding				
	Ruptured Membranes	intact	---	---	rupture
	Uterine Activity	none	irreg.	regular	---

10 The final tocolysis score represents the sum of each factor's "score" and hypothetically correlates to risk for preterm delivery as well as potential for successful tocolytic treatment. A tocolysis score of less than 3 indicates minimal risk for preterm

15 delivery (and high probability of tocolytic success) while increasingly higher scores are associated with greater risk for preterm delivery (and lower probability of successful tocolytic intervention). While the tocolysis index is a modestly accurate

20 method for assessing crude risk, it is neither reproducible between physicians (inter-observer error) nor a consistent predictor among individuals.

Kanayama and co-workers evaluated the effect of four therapeutic strategies on preterm delivery

25 rate as well as cervical expression of granulocyte elastase, a putative mediator of the labor process. The four therapeutic regimens evaluated included ritodrine infusion only (Group A), daily urinastatin vaginal suppositories (Group B), combination of

30 ritodrine infusion and vaginal urinastatin suppositories (Group C), and combination of ritodrine infusion, vaginal urinastatin suppositories, and systemic antibiotic therapy (Group D). When patients were treated with urinastatin (groups B, C and D), the

35 elastase in vaginal secretions decreased. The time

-9-

required for the number of uterine contractions (UC) to decrease to less than 1 per 30 minutes was about an hour for groups A, C and D; whereas this same UC decrease took an average of about 6 hours in group B (urinastatin alone). When UC had been depressed for 4 days, therapy was discontinued. Approximately 60% of the patients in group A experienced a recurrence; whereas, only 11-17% of the other groups experienced recurrent UC. In group A, 25% of women had premature deliveries, compared to no premature deliveries for groups B and D (9 and 8 patients, respectively) and only 1/14 in group C.

However, in the above studies, no subjects with PROM or with tocolytic scores over 4 were tested. The authors suggested that "in more advanced cases of imminent premature delivery, further studies will be needed, since it is believed that localized therapies alone are insufficient." Moreover, there was no difference between group C (ritodrine and urinastatin) and group D (ritodrine, urinastatin and antibiotic).

Fuzishiro et al. reported that a patient with history of habitual abortion was observed to have a protruding amniotic sac at 20 weeks of gestation. She was treated with vaginal antibiotics and urinastatin, tocolytics and bed rest. Her pregnancy was maintained up to 36 weeks. Japan. J. Obstet. Gynecol. Neonatal. Hematol. 2:107-10, 1992.

Urinastatin, whose use is described above, is purified from human urine. It has been reported to suppress IL-1 β -induced reduction of proteoglycan synthesis, superoxide generation, and inhibit a variety of serine proteases, such as trypsin, α -chymotrypsin, plasmin, leukocyte elastase and leukocyte cathepsin G.

35

-10-

Because urinastatin inhibits many chemical mediators in inflammation, urinastatin has been evaluated as an anti-inflammatory drug. Hence, urinastatin has been proposed for use in a variety of conditions, such as pancreatitis, septic shock, operative stress, arthritis, thrombosis and preterm delivery. It also has been proposed for use in disseminated intravascular coagulation. Inaba et al., Folia Pharmacol. Japon. 88: 239, 1986.

What is needed is an effective method to prolong pregnancy, prevent preterm delivery and reduce rates of neonatal morbidity and mortality in women with clinical signs of preterm labor.

SUMMARY OF THE INVENTION

The present invention provides a method of diagnosing and treating pregnant females at risk for impending preterm delivery. The method includes first testing for the presence of a significant amount of fetal fibronectin in the subject's vaginal or cervical secretions, which indicates that the pregnant subject is at risk for impending preterm delivery. If a significant amount of fetal fibronectin is present, the subject is administered effective amounts of a tocolytic agent, at least one urinastatin-like compound and at least one antibiotic.

In another aspect of the present invention, the method of diagnosing and treating a pregnant female at risk for impending preterm delivery includes diagnosing by testing for the presence of a significant amount of fetal fibronectin in the female's vaginal or cervical secretions. Females in whom a significant amount of fetal fibronectin is found are administered an effective amount of a tocolytic agent for less than about one week, an

-11-

effective amount of at least one urinastatin-like compound daily until 35 weeks and an effective amount of an antibiotic until the subject gives birth.

In another aspect of the present invention,
5 the method of diagnosing and treating pregnant subjects at risk for preterm delivery includes diagnosing imminent preterm delivery by means of a diagnostic test with specificity greater than 80% and sensitivity in excess of 80%. Subjects in whom the
10 diagnostic test indicates imminent preterm delivery are given effective amounts of a tocolytic agent, at least one urinastatin-like compound and at least one antibiotic.

In another aspect of the present invention,
15 there is provided a method of increasing the interval a pregnant woman carries the fetus after having been diagnosed as being at risk for imminent premature delivery. This method comprises the steps of administering an effective amount of a tocolytic
20 agent, administering an effective amount of at least one urinastatin-like compound, and administering an effective amount of at least one antibiotic.

In another aspect of this invention, the method of diagnosing and treating a pregnant female at
25 imminent risk for preterm delivery calls for determining the concentration of elastase in the cervical and/or vaginal fluids. If the female has an abnormally high level of elastase, the female is administered a tocolytic agent, at least one
30 urinastatin-like compound and at least one antibiotic.

In another aspect of this invention, there is provided the pharmaceutical composition comprising MGMTSRYFYNGTSMA, RAFIQLWAFDAVKGK and an antibiotic.

-12-

BRIEF DESCRIPTION OF DRAWING

Figure 1 shows a tabular summary of the data for pregnant women undergoing treatment according to Example 2.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention is a method for diagnosing and treating a pregnant female with impending premature delivery.

10

Definitions

As used herein, the term a "urinastatin-like compound" includes but is not limited to urinastatin, analogs and fragments thereof. Urinastatin is a glycoprotein having an approximate molecular weight of less than about 67kD in purified form. Urinastatin inhibits trypsin, elastase, granulocyte elastase, chymotrypsin, plasmin, hyaluronidase, amylase and creatine phosphokinase. In addition, urinastatin inhibits cytokine action and stabilizes lysosomal surfaces.

Urinastatin has been sequenced and described in EP publication No. 0 100 985, published 1 August 1983, which is hereby incorporated by reference. "Analogues of urinastatin" include polypeptides with conservative substitutions or deletions of amino acids which do not change the configuration, enzymatic activity, or activity in subjects. The urinastatin analogs include glycosylated and nonglycosylated polypeptides, as well as polypeptides with other post-translational changes, such as glycosylation with different sugars, acetylation, etc. The term "fragments of urinastatin" includes urinastatin analogs which are oligopeptide portions of the glycoprotein and which are active for the intended

-13-

use. Active oligopeptides include at least two peptides: the elastase inhibitor, comprising urinastatin amino acids 36-50, or MGMTSRYFYNGTSMA, and the plasmin/cytokine inhibitor, comprising urinastatin amino acids 92-106, or RAFIQLWAFDAVKGK.

"An effective amount of urinastatin" means an amount which significantly delays impending preterm delivery. An effective amount is sufficient by itself to diminish the rate of uterine contractions to about 1 in 30 minutes, within about 6 hours. An effective amount also is sufficient to depress the level of elastase in vaginal or cervical secretions significantly or to the level seen in females with normal pregnancies. The effective amount of urinastatin is preferably between about 500 and 10,000 Units per day. Preferably, the amount of urinastatin administered is about 750 to 5,000 Units per day. Even more preferably, the amount of urinastatin administered is about 1,000 U/day.

"A tocolytic agent" is defined as a drug which is capable of suppressing uterine contractions. Examples of tocolytic agents include but are not limited to ritodrine, terbutaline, salbutamol (albuterol), nifedipine and indomethacin.

"An effective amount of a tocolytic agent" means that quantity sufficient to reduce the number of uterine contractions (UC) to about 1-2 in 30 minutes within not more than 3 hours.

As used herein, "an antibiotic" includes a compound capable of killing and/or stopping multiplication of microorganisms. The microorganisms which are of greatest concern in pregnant females are the natural flora of the vagina. The microorganisms which cause very serious infections in pregnant females include anaerobes. In general, unless an

-14-

infection is present and the causative organism has been identified for treatment by a specific antibiotic, the present invention calls for the administration of a broad spectrum antibiotic.

5 Examples of broad spectrum antibiotics include amoxicillin, ampicillin, erythromycin, azithromycin, and cephalosporins. Administration of more than one antibiotic and combinations of antibiotics are contemplated in the present invention. One such
10 combination is UNASYN® ampicillin sodium/sulbactam sodium. Clindamycin is preferred as it is effective against anaerobes.

An effective amount of an antibiotic is that amount normally used to treat an infection. For
15 example, the recommended dosage of UNASYN is 1.5 to 3.0 grams every six hours. The PHYSICIAN'S DESK REFERENCE, 47th ed., 1993, lists suitable antibiotics and recommended dosages.

"Preterm delivery" means childbirth before
20 the fetus has reached about 36 completed (<37.0) weeks of gestation, as determined by patient history, ultrasound sizing, last menstrual period or other accepted methods.

"Impending or imminent preterm delivery"
25 includes delivery of a fetus with a gestational age between 24 and 34 completed weeks which occurs within 7 to 10 days of the time of diagnosis of threatened preterm delivery or preterm labor. Impending preterm delivery needs to be identified, so that appropriate
30 intervention can be undertaken to prevent premature delivery of a child whose immaturity contributes to mortality and morbidity. Impending preterm delivery is often associated with premature separation of the placenta and fetal membranes and/or premature uterine
35 contractions.

-15-

Testing for a specific marker for impending preterm pregnancy includes all the usual methods for testing substances, including solid state chemistry, chromatography and specific antibody recognition techniques. Antibody recognition techniques include various sandwich antibody assays, using radio-, fluorescent- and enzyme-linked antibodies. In the ELISA test (enzyme-linked immunoassay), enzyme-linked antibodies are subsequently exposed to chemicals on which enzymatic action causes formation of colored substances and/or substances detectable at a particular wavelength. "Fetal fibronectin" is a unique fibronectin, found in amniotic fluid, placental tissue extracts and malignant cell lines. Fetal fibronectin is distinguished by an epitope termed the "oncofetal domain." This oncofetal domain is recognizable by a specific monoclonal antibody, which is used in a highly specific and sensitive test for fetal fibronectin.

"Significant amounts of fetal fibronectin" are levels which are above the concentrations commonly observed in the cervical or vaginal secretions of females with normal pregnancies between 24 and 34 completed weeks of pregnancy. In general, fetal fibronectin concentrations greater than about 50 ng/ml, as determined by a sensitive enzyme-linked immunoassay, are considered significantly elevated. Low levels of fetal fibronectin, i.e., concentrations of less than about 50 ng/ml, are present in the cervical and vaginal secretions of females with normal, uncomplicated pregnancies between 24 and 34 completed weeks. Although fetal fibronectin may be elevated before 24 weeks of pregnancy, this elevation is due to the normal development and growth of the placenta and does not necessarily reflect poor

-16-

pregnancy outcome, e.g., preterm delivery, etc.
Between 24 and 34 completed weeks, concentrations of
fetal fibronectin greater than about 50 ng/ml in
cervical or vaginal secretions are associated with
5 preterm delivery.

"Analytical sensitivity" refers to the least
amount of analyte that can be statistically
distinguished from zero. In the present context,
"clinical sensitivity" refers to the proportion of
10 women who deliver prematurely with elevated fetal
fibronectin concentrations. Preferably, the method
for identifying female subjects with impending preterm
delivery has a clinical sensitivity of at least 80%.

"Analytical specificity" refers to the
15 test's ability to report positive results due only to
the presence of the desired analyte. Absence of
"cross-reactivity" also refers to the same phenomena
as "analytical specificity". In the present context,
"clinical specificity" refers to the proportion of
20 women with preterm deliveries in whom the fetal
fibronectin concentration in cervical or vaginal
secretions is greater than 50 ng/ml. Preferably, the
method for identifying female subjects with impending
preterm delivery has a clinical specificity of at
25 least 80%.

"Subjects" are defined as humans and
mammalian farm animals, sport animals and pets. Farm
animals include, but are not limited to, cows, hogs
and sheep. Sport animals include, but are not limited
30 to, dogs and horses. The category pets includes, but
is not limited to, cats and dogs.

GENERAL CONSIDERATIONS

The present invention provides that the
35 treatment and diagnosis of the patient at risk for

-17-

preterm delivery by a highly specific and sensitive method.

The invention provides a treatment method for impending preterm delivery. In some aspects of the invention, this method is preceded by a suitable test for preterm delivery (i.e., one with both specificity and sensitivity greater than 80%).

The treatment step comprises administration of three drugs: a tocolytic agent, a urinastatin-like drug and an antibiotic.

While not wishing to be bound by any particular theory, the inventors have observed that infection of the amniotic sac known as chorioamnionitis is a major contributor to preterm delivery. Clinical chorioamnionitis is diagnosed if the patient has leukocytosis ($\geq 10,000$ white blood cells/mm³) and the maternal temperature is above about 100.4°F and no other source of fever is found. A cervical culture may not be positive. After delivery, the placental membranes can be seen to have polymorphonuclear leukocytes. In chorioamnionitis, the levels of a variety of inflammatory modulators are increased and are thought to contribute to uterine contractions and cervical dilatation. Urinastatin has the advantage of inhibiting a variety of mediators of inflammation. In view of its broad actions, urinastatin appears well suited to inhibiting the complex array of inflammatory mediators found in chorioamnionitis. Moreover, fetal urine and amniotic fluid contain large amounts of urinastatin (Terao and Kanayama. Sanfujinka Jissai 37:158-68, 1988.) This suggests that the origin of the urinastatin is the fetus. Since urinastatin occurs naturally in fetuses and pregnant women, it would also appear to have the

35

-18-

advantage of being a relatively safe drug for the fetus and pregnant woman.

The tocolytic agent may be any known tocolytic agents. The particular tocolytic agent is not critical to the invention. Beta-mimetic agents have been popular as tocolytic agents. Such beta-mimetic agents include, but are not limited to, ritodrine, terbutaline, and albuterol (salbutamol). Other tocolytic agents are believed to suppress uterine contractility by inhibiting the release of intracellular calcium, including for example, magnesium sulfate and nifedipine calcium antagonist/calcium channel blocker. Anti-prostaglandins, such as indomethacin, and have also been suggested for use as tocolytic agents but are effective for only a short time and have significant maternal and fetal toxicity.

The tocolytic agent generally is administered systemically. Although any systemic route of administration can be used, preferred routes include, but are not limited to, the intravenous and oral routes. The intravenous route may be preferred initially to develop high blood levels quickly; however, the oral route is often preferred, particularly if longer term maintenance therapy and drug administration are required.

A urinastatin-like compound includes but is not limited to urinastatin, urinastatin analogs, and urinastatin fragments. Urinastatin is a glycoprotein having an approximate molecular weight less than about 67kD in a purified form. Urinastatin inhibits trypsin, elastase, granulocyte elastase, chymotrypsin, plasmin, hyaluronidase, amylase and creatine phosphokinase. Urinastatin has been described as inhibiting cytokine action and stabilizing lysosomal

-19-

surfaces. At least a portion of the peptide urinastatin has been sequenced (EP publication No. 0 100 985, published 1 August 1983).

Urinastatin-like compounds include
5 urinastatin which has been isolated from natural sources. Natural sources include, but are not limited to, the urine of human men (as used by Mochida Pharmaceutical Co., Ltd., Tokyo, Japan). Urinastatin from natural sources may be further processed to
10 obtain active subunits or fragments. Urinastatin may also be synthesized by either chemical or recombinant nucleic acid methods. A urinastatin-like compound can be synthesized recombinantly in homologous and heterologous cells. A urinastatin-like compound can
15 be synthesized in E. coli or Chinese hamster ovary (CHO) cells. Techniques for synthesis of polypeptides are described, for example, in Merrifield, J. Amer. Chem. Soc. 85:2149-2156, 1963, incorporated herein by reference.

20 Analogues of urinastatin include substituted peptides which have the same active configuration as urinastatin itself. Analogues of urinastatin include polypeptides with conservative substitutions or deletions of amino acids which do not change the
25 configuration, enzymatic activity, or activity in subject. Urinastatin analogues include glycosylated and nonglycosylated polypeptides, as well as polypeptides with other post-translational changes, such as glycosylation with different sugars, acetylation, etc.

30 Analogues of urinastatin also include suitable fragments, such as those portions of the protein which are effective for the intended use. Active oligopeptides include, but are not limited to, the
35 following two peptides: an elastase inhibitor,

-20-

comprising amino acids 36-50, or MGMTSRYFYNGTSMA, and an inhibitor of plasmin, trypsin and cytokines, comprising amino acids 92-106, or RAFIQLWAFDAVKGK. A "fragment" of urinastatin includes peptides that are smaller in size than urinastatin and may be comprised of peptides of from about amino acid 36 to about amino acid 106 wherein the peptide is at least about 10 amino acids in length, preferably about 15 amino acids in length. For these relatively short oligopeptides, chemical synthesis may be preferred over recombinant synthesis.

The active oligopeptides may be administered individually or together. Further, fragments of urinastatin may be administered alone or with a tocolytic agent and/or an antibiotic. More preferred is their administration together. In a preferred embodiment both peptides are formulated in a vaginal suppository which also contains at least one antibiotic, preferably a cephalosporin. Another alternative is administration of one or both of the active oligopeptides conjugated to an antibiotic. One such example is the pharmaceutical conjugated compound MGMTSRYFYNGTSMA-RAFIQLWAFDAVKGK-antibiotic. Even more preferably, the antibiotic of the conjugated compound is a cephalosporin. The conjugation of the oligopeptides to the antibiotic can be performed by carboxyl and/or amide linkages using biochemical techniques well known in the art.

A urinastatin-like compound may be administered systemically or locally. More preferred is local administration. Most preferred is intravaginal administration. Vaginal administration of the urinastatin-like compound can be performed in several other ways, including douche, suppository, foam and gel forms. In the form of a douche, an

-21-

aqueous solution of the urinastatin-like compound is directed against the cervix. Preferably, the urinastatin-like compounds is administered in a solid or semi-solid form (foam, gel or suppository) which
5 retains the urinastatin at the site of administration, preferably near the cervix.

The most preferred delivery form for a urinastatin-like compound is a vaginal suppository, which is a solid dosage form varying in weight and
10 shape. After insertion, suppositories soften, melt or dissolve in the cavity fluids. Vaginal suppositories are usually globular or oviform and generally weigh about 5 grams. The usual suppository bases are cocoa butter, glycerinated gelatin, hydrogenated vegetable
15 oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. Use of cocoa butter (also known as theobroma oil or cocoa oil) is preferred. Cocoa butter melts quickly at body temperature.

Water-miscible suppository bases also may be
20 used. Examples include polyethylene glycols or glycol-surfactant combinations. Polymers of ethylene glycol are available as polyethylene glycol polymers (Carbowax, polyglycols) of assorted molecular weights.
25 Glycerinated gelatin is also often used as a vehicle for vaginal suppositories. Water-miscible suppository bases have the advantage of lack of dependence on a melting point approximating body temperature. Problems of handling, storage and shipping are
30 simplified considerably.

Suppositories are prepared by well known methods including rolling (hand-shaping), molding (fusion) and cold compression.

The urinastatin-like compound is preferably
35 administered as a single daily dose. However, the

-22-

urinastatin-like compound also may be administered in two or more divided doses.

The preferred mode for preparing the urinastatin suppository is given in Example 1.

5 The antibiotic or combination of antibiotics contemplated in the present invention are those indicated by either diagnosis or suspected presence of microorganisms and include, for example, broad spectrum antibiotics and preferably antibiotics which
10 are known to be effective against anaerobic bacteria. The particular antibiotic is not critical. Examples of broad spectrum antibiotics include amoxicillin, ampicillin, erythromycin, azithromycin, and cephalosporin. Clindamycin is preferred because it is
15 effective against anaerobes. Use of more than one antibiotic, including combination antibiotics, is also contemplated in the present invention. One such combination is UNASYN® ampicillin sodium/sulbactam sodium (Roerig, Pfizer, Inc., New York, NY).

20 An effective amount of an antibiotic is that amount normally used to treat an infection. For example, the recommended dosage of UNASYN is 1.5 to 3.0 grams every six hours. The antibiotic can be administered systemically or locally. For systemic
25 administration, oral administration is preferred; however, other methods, such as intravenous and intramuscular administration also can be used. For local administration, the antibiotic can be inserted vaginally, in the form of a cream, suppository or
30 other suitable dosage form.

 Various regimens for administering the antibiotic(s) can be utilized. For example, mezlocillin may be given intravenously for 48 hours and followed by oral ampicillin until the delivery.
35 Other dual antibiotic regimens comprise intravenous

-23-

ampicillin/oral erythromycin and
ampicillin/gentamicin. A preferred three-antibiotic
regimen includes ampicillin, gentamicin and
clindamycin.

5 The tocolytic, urinastatin-like compound and
antibiotic can be administered for various period of
time. In one regimen, the subject is administered an
effective amount of a tocolytic agent for less than
about one week, an effective amount of at least one
10 urinastatin like compound daily until 35 weeks, and an
effective amount of an antibiotic until the subject
gives birth.

 It is, of course, understood that the
dosage, timing and administration requirements for the
15 tocolytic agent, urinastatin-like compounds and
antibiotics may differ from subject to subject and are
to be determined by the person responsible for
treating the subject, without undue experimentation
and using techniques known within the art.

20 In another aspect, the above-described
treatment steps are preceded by the diagnosis of
impending preterm delivery. Diagnosis comprises
testing for females who are at risk for preterm
delivery with a method which is highly sensitive and
25 specific for such a condition. Any suitable marker
for preterm delivery can be used, so long as the test
for the marker sufficiently distinguishes females at
risk for preterm delivery from females who will not
deliver early. A preferred test for impending preterm
30 delivery has both specificity and sensitivity greater
than about 80%. A particularly preferred method is a
test for fetal fibronectin. Most preferred is an
ELISA test for fetal fibronectin. An ELISA test of
this type may be performed as follows.

35

-24-

The mucosal sample to be tested is obtained from the cervix or the posterior fornix of the vagina on a swab. The swab is placed in buffer, in which the mucosal sample is diluted. Next, the concentration of fetal fibronectin is measured with an ELISA test (Fetal Fibronectin Immunoassay, Adeza Biomedical, Sunnyvale, CA). This assay utilizes a monoclonal antibody specific for the oncofetal antigen, followed by a goat anti-human plasma fibronectin IgG conjugated to alkaline phosphatase and a phenolphthalein monophosphate substrate. The absorbance of each standard and sample was determined at a wavelength of 550 nm with an automated microtiter-plate reader, and fetal-fibronectin concentrations were derived from the SoftMax software program (Molecular Devices, Menlo Park, CA). Values greater than about 50 ng/ml, determined during weeks 21-37 of pregnancy, are significant amounts and considered predictive of impending preterm delivery.

The invention has been disclosed by direct description. The following are examples showing the efficacy of the method in diagnosing and preventing premature births in female subjects. The examples are only examples and should not be taken in any way as limiting to the scope of the method.

EXAMPLES

Example 1

Pyrogen-free urinastatin powder (Miraclid® brand) was obtained from Mochida Pharmaceutical Co., Tokyo, Japan. This powder was prepared from the fresh urine of healthy men, generally according to the method of Proksch and Routh (J. Clin. Lab. Med. 79:491, 1972). The dose of urinastatin was expressed in units; one unit of urinastatin inhibits 2 µg of

-25-

trypsin (3200 NFU/mg, Canada Packers, Toronto, Ontario, Canada) by 50% according to the method of Kassel (Methods Enzymol. 19:844, 1970).

5 A batch of urinastatin suppositories was prepared as follows: 300,000 units of UTI powder (prepared as described above) was dissolved in 300 ml of Uretebsol W 35 sorbent for suppositories (Mochida Co., Tokyo, Japan) at 55°C. The main ingredient of Uretebsol W 35 is cocoa butter.

10 Next, into plastic trays with 1 ml receptacles, 1 ml aliquots of the UTI solution were poured. The trays were stored at 4°C for about 2 hours. By then the suppositories had set, were firm and were ready to use. The completed suppositories are
15 preferably stored at room temperature (20-25° C).

Example 2

168 patients in their 24th to 35 week of pregnancy were diagnosed with imminent premature
20 delivery. The diagnosis of imminent premature delivery was based on a tocolysis index of 2 or greater. Factors of cervical dilation, ruptured membranes, uterine activity and vaginal bleeding were considered for the tocolysis index. The tocolysis
25 index was determined by evaluating these factors and assigning points as shown in the following table. The index is the sum of these points.

30

35

-26-

		<u>Tocolysis Index</u>			
		<u>0 pts</u>	<u>1 pt</u>	<u>2 pts</u>	<u>3 pts</u>
	Cervical Dilation	0 cm	1 cm	2 cm	3 cm
5	Vaginal Bleeding	none	---	spotting	
	bleeding				
	Ruptured Membranes	intact	---	---	rupture
	Uterine Activity	none	irreg.	regular	---
10	A number of regimens were compared. Group 1 received ritodrine intravenous infusion at 50-300 μ g per day. Groups 2 and 3 were given daily urinastatin suppositories containing 5000 units and 1000 units, respectively. Group 4 received IV ritodrine at 50-300				
15	μ g per day and one 1000 unit urinastatin suppository per day. Group 5 received IV ritodrine at 50-300 μ g per day, one 1000 unit urinastatin suppository per day, and cephalosporin. The patients were treated until they delivered.				
20	A number of parameters were tracked and are reported in Figure 1. The tocolysis index immediately before the start of treatment varied from 2-8. Elastase levels obtained from specimen of endocervical secretions were determined at admission to the study.				
25	"Hours to Neg UA", or the time until the number of uterine contractions in 30 minutes decreased to one or less, was reported. "Recur UA", or the proportion of women experiencing recurrence of at least one uterine contraction every 30 minutes after therapy lasting 4				
30	days or longer was discontinued also was observed. "EGA Toco" is the estimated gestational age at the beginning of therapy. "EGA Del" is the estimated gestational age at delivery. The "interval" is the number of weeks between EGA Toco and EGA Del. "PTD<37				
35	Wks" is the number of preterm births before 37 weeks.				

-27-

"PTD<34 Wks" is the number of preterm births before 34 weeks, or seriously premature infants.

All groups were comparable in maternal age, parity, estimated gestational age at start of study, tocolysis index and elastase level. However, group 5 had a relatively higher percentage of patients with tocolysis indices ≥ 6 .

While treatment with ritodrine reduced uterine contractions more rapidly (1.4 hr compared to a study average of 3.1 hr) than other drug combinations, ritodrine alone had the highest rate of recurrence of uterine activity (over 30%) in spite of continuous administration of the drug. Finally, preterm deliveries of less than 34 and 37 wk accounted for approximately 21% and 42%, respectively, of all deliveries in women treated with ritodrine alone.

Women receiving only UTI suppositories (Group 3) experienced a slower expression of uterine activity than women receiving ritodrine, but in contrast, the recurrence rate of uterine activity was lower as was the proportion of deliveries occurring before 34 wk and 37 wk. As might be expected, combination of UTI and ritodrine rapidly suppressed uterine activity and diminished the recurrence of uterine activity. The proportion of deliveries occurring prior to 34 and 37 wk was not diminished compared to treatment with UTI alone. The combination of UTI, ritodrine and cephalosporin successfully suppressed uterine contractility, lowered the recurrence rate of uterine activity, and unexpectedly lowered the proportion of deliveries occurring before 34 and 37 wks.

Thus, the combination of ritodrine, urinastatin and cephalosporin was surprisingly more

-28-

successful than the drugs alone or the combination of ritodrine and urinastatin.

Example 3

5 Patients are diagnosed as having risk of imminent preterm delivery by means of the fetal fibronectin immunoassay are treated with a combination of ritodrine (a tocolytic), urinastatin (UTI) and cephalosporin antibiotic.

10 Mucous samples are obtained from women whose gestation period is less than about 34 weeks and who have signs and symptoms indicative of preterm delivery. The fetal fibronectin level is determined by a method which has both specificity and sensitivity
15 greater than 80%. The mucous sample to be tested is obtained from the cervix or the posterior fornix of the vagina on a swab. The swab is placed in buffer, which dilutes the mucous sample. Next, the concentration of fetal fibronectin is measured with an
20 ELISA test (Fetal Fibronectin Immunoassay, Adeza Biomedical). This assay utilizes a monoclonal antibody specific for the oncofetal antigen, followed by a goat anti-human plasma fibronectin IgG conjugated to alkaline phosphatase and a phenolphthalein
25 monophosphate substrate. The absorbance of each standard and sample was determined at a wavelength of 550 nm with an automated microtiter-plate reader. Fetal-fibronectin concentrations were derived from the SoftMax software program (Molecular Devices). Patient
30 with fetal fibronectin values greater than about 0.05 $\mu\text{g/ml}$, determined during weeks 21-37 of pregnancy, are considered to be at highest risk for impending preterm delivery (at risk of delivering within about seven days) and are entered into one of the following
35 treatment groups.

-29-

Group A patients are given ritodrine drip infusion therapy; Group B patients are given daily UTI suppository therapy (about 1000 units/suppository); Group C patients are given a combination of daily UTI suppository and ritodrine drip infusion therapy; and Group D patients are given a combination of ritodrine infusion, UTI suppository and oral cephalosporin therapy. After treatment, the times to depress uterine contractions are monitored after four days of therapy. After four days of therapy, treatments are stopped but UC are monitored by a belt apparatus.

Example 4

Females whose fetal fibronectin values exceed 0.05 $\mu\text{g/ml}$ during weeks 21-37 of pregnancy are randomly assigned to treatment groups to receive ritodrine alone, UTI alone or combination therapy of ritodrine, UTI and antibiotic as described in Example 3. For each treatment group, patients' fetal fibronectin values before the start of therapy are plotted against the rate of premature births to determine the effect of therapy on more or less risk-prone patients.

This invention has been detailed both by example and by direct description. It should be apparent that one having ordinary skill in this art would be able to surmise equivalents to the invention as described in the claims which follow but which would be within the spirit of the description above. Those equivalents are to be included within the scope of this invention.

35

-30-

CLAIMS

1. A method of diagnosing and treating a pregnant female subject at risk for impending preterm delivery, said method comprising the steps of
 - (a) testing for the presence of a significant amount of fetal fibronectin in the subject's vaginal or cervical secretions; and
 - (b) if a significant amount of fetal fibronectin is present, administering to the subject the following:
 - (i) a tocolytic agent;
 - (ii) at least one urinastatin-like compound; and
 - (iii) at least one antibiotic.
2. A method of diagnosing and treating a pregnant female subject at risk for impending preterm delivery, said method comprising the steps of
 - (a) testing for the presence of a significant amount of fetal fibronectin in the subject's vaginal or cervical secretions; and
 - (b) if a significant amount of fetal fibronectin is present, administering to the subject
 - (i) an effective amount of a tocolytic agent for less than about 1 week;
 - (ii) an effective amount of at least one urinastatin-like compound daily until 35 weeks; and
 - (iii) an effective amount of an antibiotic until the subject gives birth.
3. A method of diagnosing and treating a pregnant female subject at risk for impending preterm delivery, said method comprising the steps of

-31-

(a) diagnosing imminent preterm delivery by a method which has a sensitivity of at least 80% and a specificity of at least 80%; and

5 (b) if the subject is diagnosed with imminent preterm delivery, administering to the subject the following:

(i) a tocolytic agent;

(ii) at least one urinastatin-like compound; and

10 (iii) at least one antibiotic.

4. A method of diagnosing and treating a pregnant female subject at imminent risk for preterm delivery, said method comprising the steps of

15 (a) testing for the concentration of elastase in the cervical and/or vaginal fluids; and

(b) administering to the subject with an abnormally high level of elastase the following:

(i) a tocolytic agent;

20 (ii) at least one urinastatin-like compound; and

(iii) at least one antibiotic.

5. A method of increasing the interval a pregnant woman carries the fetus after having been diagnosed with imminent premature delivery, said method comprising the steps of

25 (a) administering an effective amount of a tocolytic agent;

30 (b) administering an effective amount of at least one urinastatin-like compound; and

(c) administering an effective amount of at least one antibiotic.

35

-32-

6. The method of claim 1 wherein the urinastatin-like compound is selected from the group consisting of urinastatin, urinastatin analogs and urinastatin oligopeptide fragments.

5

7. A method for treating a pregnant female for imminent preterm delivery, said method comprising administering a urinastatin oligopeptide fragment of at least about 10 amino acids in length and having elastase inhibiting activity.

10

8. A method for treating a pregnant female for imminent preterm delivery, said method comprising administering a urinastatin oligopeptide fragment of at least about 10 amino acids in length and having plasmin/cytokine inhibiting activity.

15

9. The method of claims 1, 2, 3 or 4 wherein the step of testing for fibronectin is performed by an immunoassay which is specific for the fetal form of fibronectin.

20

10. The method of claims 6, 7 or 8 wherein the oligopeptide fragments comprise amino acids of from about amino acid 36 to about amino 106 of the urinastatin amino acid sequence.

25

11. The method of claim 10 wherein amino acids are the amino acids of from about 36-50 and comprise the sequence MGMTSRIFYNGTSMA.

30

12. The method of claim 10 wherein amino acids are the amino acids of from about 92-106 and comprise the sequence RAFIQLWAFDAVKGK.

35

-33-

13. The method of claim 10 wherein both the sequences MGMTSRYFYNGTSMA and RAFIQLWAFDAVKGK are administered.

5 14. The method of claims 6, 7 or 8 further comprising administering a tocolytic agent.

10 15. The method of claims 6, 7 or 8 further comprising administering an antibiotic.

16. The method of claims 1, 2, 3, 4 or 5 wherein the tocolytic agent is selected from the group consisting of ritodrine, terbutaline, albuterol, magnesium sulfate, and indomethacin.

15 17. The method of claim 14 wherein the tocolytic agent is selected from the group consisting of ritodrine, terbutaline, albuterol, magnesium sulfate, and indomethacin.

20 18. The method of claims 1, 2, 3, 4 or 5 wherein the antibiotic is selected from the group consisting of amoxicillin, ampicillin, erythromycin, cephalosporin, clindamycin, sulbactam sodium, and gentamicin.

25 19. The method of claim 15 wherein the antibiotic is selected from the group consisting of amoxicillin, ampicillin, erythromycin, cephalosporin, 30 clindamycin, sulbactam sodium, and gentamicin.

20. The pharmaceutical composition of the peptides MGMTSRYFYNGTSMA and RAFIQLWAFDAVKGK in combination with an antibiotic.

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/12751

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00

US CL : 514/12, 13, 14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 13, 14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, CAB ABSTRACTS

search terms: inter(2a)trypsin, urinastatin, preterm delivery, pregnan?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Biological Abstracts, issued 1992, Kanayama et al, "The Effect of Granulocyte Elastase Inhibitor Urinastatin Vaginal Suppository on Patients with Imminent Premature Delivery", Acta Obstet. Gynaecol. Jpn., 44(4), pages 477-482, see entire abstract.	1-20
Y	New England Journal of Medicine, Volume 325, No. 10, issued 05 September 1991, C. L. Lockwood et al, "Fetal Fibronectin in Cervial and Vaginal Secretions as a Predictor of Preterm Delivery", pages 669-674, see entire document.	1-20

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 JANUARY 1995

Date of mailing of the international search report

17 FEB 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHEELA J. HUFF

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/12751

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Am. J. Obstet. Gynecol., Volume 168, No. 2, issued February 1993, J. C. Morrison et al, "Oncofetal fibronectin in patients with false labor as a predictor of preterm delivery", pages 538-542, see entire document.	1-20